KaydedilenlerDerginizi ekleyin

Dergiler / The Anatolian Journal of Cardiology / 2017 / Cilt: 18 - Sayı: 2

Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients

Qiang TAN
Shuangyue ZHANG
Xiaoyi ZOU
Jun ZHAO
Jia HAO
Qian SUN
Sayfa
103–107
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This may occur because of depressing inflammation and improving circulating EPCs

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: This study aimed to evaluate whether fluvastatin therapy could decrease the probability of atrial fibrillation (AF) progression from paroxysmal AF to permanent AF and decrease the recurrence frequency of AF.Methods: Analyses were performed using two-tailed Student’s t test or Mann-Whitney U tests.
📊
Temel Bulgular & Veri:Categorical variables were compared with the χ2statistics or Fisher’s exact test.
💡
Sonuç & Katkı:This may occur because of depressing inflammation and improving circulating EPCs
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: This study aimed to evaluate whether fluvastatin therapy could decrease the probability of atrial fibrillation (AF) progression from paroxysmal AF to permanent AF and decrease the recurrence frequency of AF.Methods: Analyses were performed using two-tailed Student’s t test or Mann-Whitney U tests. Categorical variables were compared with the χ2statistics or Fisher’s exact test. Patients with paroxysmal AF were randomized case-control, prospective into either the fluvastatin group (n=61) or control group (n=57). Patients were followed up for 24 months. The primary endpoint event was paroxysmal AF that progressed to permanent AF. Secondary endpoints were AF recurrence, cardiac dysfunction, stroke, or death.Results: There were no differences in AF progression (fluvastatin group, 8.19% vs. control group, 12.51%; p>0.05) and stroke (fluvastatin group. 6.55% vs. control group. 8.77%; p>0.05). Patients in the fluvastatin group had a lower rate of AF recurrence (fluvastatin group, 24.59% vs. control group, 49.12%; p<0.05) and a lower rate of cardiac dysfunction (fluvastatin group, 6.55% vs. control group, 19.29%; p<0.05). Death did not occur in both the groups. After 1 week of fluvastatin therapy, C-reactive protein (CRP) and homocysteine (HCY) levels were lower in the fluvastatin group than in the control group. At 24 months of follow-up, CRP and HCY levels remained lower in the fluvastatin group than in the control group. The number of endothelial progenitor cells (EPCs) increased in the fluvastatin group compared with that in the control group (fluvastatin group, 72.27±12.49 counts/105 vs. control group, 57.45±8.24 counts/105, p=0.001).Conclusion: Fluvastatin therapy could not decrease AF progression. However, it could decrease the recurrence frequency of paroxysmal AF and cardiac dysfunction. This may occur because of depressing inflammation and improving circulating EPCs

🔖

Bu Makaleye Atıf Yap

TAN, Q., ZHANG, S., ZOU, X., ZHAO, J., HAO, J., SUN, Q. (2017). Fluvastatin therapy could not decrease progression of paroxysmal atrial fibrillation in non-valvular disease patients. The Anatolian Journal of Cardiology, Cilt: 18 - Sayı: 2, 103–107. https://ajindex.com/articles/365423

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Lip G, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: One year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).Eur Heart J 2014; 35: 3365-76
  2. Galea R, Cardillo MT, Caroli A, Marini MG, Sonnino C, Narducci ML, et al. Inflammation and C-reactive protein in atrial fibrillation: cause or effect? Tex Heart Inst J 2014; 41: 461-8
  3. Im SI, Chun KJ, Park SJ, Park KM, Kim JS, On YK. Long-term Prognosis of paroxysmal atrial fibrillation and predictors for progression to persistent or chronic atrial fibrillation in the Korean population. J Korean Med Sci 2015; 30: 895-902
  4. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79: 495- 902
  5. Warita S, Kawasaki M, Tanaka R, Ono K, Kojima T, Hirose T, et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients. A prospective study of 2-Years’ Follow-up. Circ J 2012; 76: 2755-62
  6. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm 2012; 9: 632-96
  7. Tan Q, Wang Q, Zhang S, Qi X, Li Y. Circulating endothelial progenitor cells were increased in patients with thin-cap fibroatheroma. Clin Lab 2016; 62: 2233-40
  8. Polovina MM, Ostojic MC, Potpara TS. Relation of biomarkers of infammation and oxidative stress with hypertension occurrence in lone atrial fibrillation. Mediators Inflamm 2015; 2015: 653026
  9. Kusayama T, Furusho H, Kashiwagi H, Kato T, Murai H, Usui S, et al. Inflammation of left atrial epicardial adipose tissue is associated with paroxysmal atrial fibrillation. J Cardiol 2016; 68: 406-11
  10. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96: 1180-4
  11. Folkeringa RJ, Tieleman RG, Maessen JG, Prins MH, Nieuwlaat R, Crijns H. Statins do not reduce atrial fibrillation after cardiac valvular surgery: A single centre observational study. Neth Heart J 2011; 19: 17-23. 12.